<DOC>
	<DOCNO>NCT02889692</DOCNO>
	<brief_summary>The investigator perform randomize , double blind control , prospective study method observation Traditional Chinese Medicine ( TCM ) combine targeted therapy maintenance prolong efficacy long-term survival advance pulmonary adenocarcinoma patient . The investigator plan involve 200 case observation 3 year ( 100 case target therapy maintenance , 100 case target therapy maintenance plus TCM , ) , expect integrate TCM combine targeted maintenance therapy well efficacy prolong progression-free survival time , overall survival , improve quality life ( QOL ) patient target maintenance therapy .</brief_summary>
	<brief_title>Clinical Study Chinese Medicine Plus Targeted Therapy Maintenance Advanced Pulmonary Adenocarcinoma</brief_title>
	<detailed_description>Maintenance therapy refers systemic therapy may give patient advance NSCLC 4 6 cycle first-line chemotherapy . However , patient candidate maintenance therapy respond previous treatment stable disease tumor progress . Epidermal growth factor receptor tyrosine kinase inhibitor ( EGFRTKIs ) Iressa Erlotinib prove effective first second line therapy advance pulmonary adenocarcinoma . Targeted therapy maintenance partly extend patient 's TTP , toxicity side effect target therapy decrease QOL . Besides , high cost target therapy cause great economic pressure patients.The investigator ' preliminary study show traditional Chinese medicine ( TCM ) prolong survival time improve QOL , high-level evidence need . The investigator perform multicenter , randomize , double blind control , prospective study advance pulmonary adenocarcinoma patient stage Ⅲ～Ⅳ . Advanced pulmonary adenocarcinoma patient first-line chemotherapy choose maintenance therapy accord patient 's wish , include target therapy maintenance , chemotherapy maintenance TCM maintenance therapy . Patients choose target therapy maintenance randomize observational group ( TCM granules plus targeted therapy maintenance ) , control group ( TCM placebo plus targeted therapy maintenance ) . The treatment continue evidence disease progression unacceptable toxicity , regular follow-up arrange . The primary efficacy assessment : OS ( overall survival ) ; Secondary efficacy assessment : ( 1 ) PFS ( progression-free survival ) ; ( 2 ) Objective response rate ; ( 3 ) QOL ( Functional Assessment Cancer therapy-lung , FACT-L4.0 scale ; Lung Cancer Symptom Scale , LCSS ) ; ( 4 ) efficacy assessment : 1 ) TCM symptom change ; 2 ) Toxicity , side effect security treatment assess time . The investigator expect integrate TCM combine targeted therapy maintenance well efficacy prolong progression-free survival time , overall survival , improve QOL patient target therapy maintenance . Therefore study provide evidence optimize promote integrate TCM combine Western Medicine treatment .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Pathologically cytologically confirm stage IIIaIV pulmonary adenocarcinoma ; 2 . The efficacy evaluation firstline therapy progressionfree include complete response ( CR ) , partial response ( PR ) stable disease ( SD ) ; 3 . Age ≥18 year old ; 4 . Physical status score ( ECOG PS ) ≤ 2 score ; 5 . Estimated life expectancy least 12 week ; 6 . Participants major organ dysfunction : hemoglobin ≥9 g/dL , absolute neutrophil count ( ANC ) ≥1.5*109/L , platelet ≥100 *109/L , bilirubin ≤1.5ULN , alkaline phosphatase ( AP ) , aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤2.5 upper limited number ( ULN ) ( AP , AST , ALT ≤5ULN acceptable liver tumor involvement ) .INR≤1.5 , APTT normal range ( 1.2DLN1.2ULN ) , creatinine ≤1.5ULN ; 7 . Planning targeted maintenance . 8 . Informed consent patient . 1 . The efficacy evaluation firstline therapy progressive disease ( PD ) ; 2 . Patient malignant tumor except NSCLC 5 year previous study entry ; 3 . Patient already receive chemotherapy anticancer treatment ; 4 . Estimated life expectancy le 12 week ; 5 . Brain metastasis ( control brain metastasis steroid free need exclude ) ; 6 . History cardiovascular disease : Congestive Heart Failure &gt; grade II NYHA.Unstable angina patient ( angina symptom rest ) new occurrence angina ( begin last 3 month ) myocardial infarction happen last 6 month ; 7 . Pregnant child breast feeding woman ; 8 . Mental cognitive disorder ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>traditional Chinese medicine</keyword>
	<keyword>maintenance therapy</keyword>
	<keyword>target therapy</keyword>
</DOC>